NYSE:ZYME Zymeworks (ZYME) Stock Price, News & Analysis → 1970’s computer coder Issues Shocking AI Warning (From InvestorPlace) (Ad) Free ZYME Stock Alerts $9.23 +0.17 (+1.88%) (As of 03:33 PM ET) Add Compare Share Share Today's Range$8.95▼$9.3450-Day Range$8.11▼$12.5152-Week Range$6.01▼$13.14Volume262,189 shsAverage Volume594,935 shsMarket Capitalization$652.65 millionP/E RatioN/ADividend YieldN/APrice Target$12.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsSocial Media Get Zymeworks alerts: Email Address Zymeworks MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside36.8% Upside$12.67 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment-0.08Based on 15 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.04) to ($0.37) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.45 out of 5 starsMedical Sector693rd out of 915 stocksPharmaceutical Preparations Industry327th out of 426 stocks 3.3 Analyst's Opinion Consensus RatingZymeworks has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageZymeworks has only been the subject of 3 research reports in the past 90 days.Read more about Zymeworks' stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for ZYME. Previous Next 0.0 Dividend Strength Dividend YieldZymeworks does not currently pay a dividend.Dividend GrowthZymeworks does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ZYME. Previous Next 1.6 News and Social Media Coverage News SentimentZymeworks has a news sentiment score of -0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.36 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Zymeworks this week, compared to 2 articles on an average week.MarketBeat Follows4 people have added Zymeworks to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Zymeworks insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.22% of the stock of Zymeworks is held by insiders.Percentage Held by Institutions92.89% of the stock of Zymeworks is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Zymeworks' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Zymeworks are expected to grow in the coming year, from ($1.04) to ($0.37) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Zymeworks is -5.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Zymeworks is -5.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioZymeworks has a P/B Ratio of 1.50. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Zymeworks' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlace1970’s computer coder Issues Shocking AI WarningLouis Navellier has spent four decades building a billion-dollar empire on the back of big data and technology… Now he's stepping forward with a shocking warning about how AI will soon impact the wealth of everyday Americans.Click here to watch his new video ASAP About Zymeworks Stock (NYSE:ZYME)Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.Read More ZYME Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ZYME Stock News HeadlinesMay 9, 2024 | americanbankingnews.comZymeworks (NYSE:ZYME) Stock Rating Reaffirmed by HC WainwrightMay 8, 2024 | markets.businessinsider.comHold Rating on Zymeworks: Balancing Potential Rewards and Valuation RisksMay 9, 2024 | Stansberry Research (Ad)Things Are Not Normal in America – Here’s What to DoGet Out of the Dollar Before May 15 A Wall Street legend and our friend has just warned 896,000 Americans to prepare for May 15.May 7, 2024 | benzinga.comZymeworks Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)May 6, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYMEMay 5, 2024 | americanbankingnews.comWells Fargo & Company Lowers Zymeworks (NYSE:ZYME) Price Target to $12.00May 5, 2024 | americanbankingnews.comCitigroup Lowers Zymeworks (NYSE:ZYME) Price Target to $16.00May 3, 2024 | markets.businessinsider.comOptimistic Buy Rating for Zymeworks: Anticipated Approvals and Strong Pipeline PotentialMay 9, 2024 | Stansberry Research (Ad)Things Are Not Normal in America – Here’s What to DoGet Out of the Dollar Before May 15 A Wall Street legend and our friend has just warned 896,000 Americans to prepare for May 15.May 3, 2024 | markets.businessinsider.comBuy Rating Affirmed for Zymeworks on Strong Pipeline and Upcoming CatalystsMay 3, 2024 | finance.yahoo.comZymeworks Inc. (NYSE:ZYME) Q1 2024 Earnings Call TranscriptMay 3, 2024 | finance.yahoo.comZymeworks Inc (ZYME) (Q1 2024) Earnings Call Transcript Highlights: Navigating Challenges and ...April 30, 2024 | globenewswire.comZymeworks Announces Participation in Upcoming Investor ConferencesApril 28, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYMEApril 20, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYMEApril 18, 2024 | seekingalpha.comBuy Zymeworks Pioneering Cancer Treatments: Zanidatamab's Promising DataApril 16, 2024 | markets.businessinsider.comLevi & Korsinsky Reminds Shareholders of an Investigation into Zymeworks Inc. (ZYME) Regarding Potential Securities Fraud AllegationsApril 12, 2024 | markets.businessinsider.comMaintaining Hold on Zymeworks: ZW191’s Potential Amidst Competitive and Regulatory HurdlesApril 12, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYMEApril 11, 2024 | globenewswire.comZymeworks To Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024April 8, 2024 | globenewswire.comZymeworks Presents New Data from Multiple Preclinical Development Programs at 2024 American Association for Cancer Research Annual MeetingApril 4, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYMEApril 4, 2024 | morningstar.comKirby McInerney LLP Announces Investigation of Shareholder Claims Against Zymeworks Inc. (ZYME)April 2, 2024 | stockhouse.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYMEMarch 28, 2024 | finanznachrichten.deZymeworks Inc.: Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of DirectorsMarch 28, 2024 | globenewswire.comZymeworks Announces Appointment of Dr. Neil Gallagher to its Board of DirectorsMarch 27, 2024 | globenewswire.comZymeworks Announces Participation in Upcoming Investor ConferencesSee More Headlines Receive ZYME Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zymeworks and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/06/2024Today5/09/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSE:ZYME Previous SymbolNASDAQ:ZYME CUSIPN/A CIK1403752 Webwww.zymeworks.com Phone(302) 274-8744Fax604-737-7077Employees272Year FoundedN/APrice Target and Rating Average Stock Price Target$12.67 High Stock Price Target$16.00 Low Stock Price Target$10.00 Potential Upside/Downside+40.6%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-118,670,000.00 Net Margins-249.63% Pretax Margin-253.36% Return on Equity-28.37% Return on Assets-21.98% Debt Debt-to-Equity RatioN/A Current Ratio6.92 Quick Ratio6.92 Sales & Book Value Annual Sales$76.01 million Price / Sales8.38 Cash FlowN/A Price / Cash FlowN/A Book Value$6.19 per share Price / Book1.46Miscellaneous Outstanding Shares70,710,000Free Float69,842,000Market Cap$637.10 million OptionableOptionable Beta1.16 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. Kenneth H. Galbraith C.A. (Age 61)CEO & Chairman of the Board Comp: $1.04MDr. Christopher Astle Ph.D. (Age 43)Senior VP & CFO Comp: $682.22kDr. Paul Moore Ph.D. (Age 56)Chief Scientific Officer Comp: $872.67kMr. Mark Hollywood (Age 54)Executive VP and Head of Technical & Manufacturing Operations Mr. Daniel Dex J.D.Ph.D., Senior VP, Corporate Secretary & General CounselDiana PapoveSenior Manager of Corporate CommunicationsDr. Lindsey Foulkes B.Sc.Ph.D., Vice President of Corporate DevelopmentMs. Laura O'ConnorVice President of Human Resources & DEIDr. Jeffrey Smith M.D.Executive VP & Chief Medical OfficerDr. Josemund Menezes MBBSManaging Director of Early-Stage Development for Asia PacificMore ExecutivesKey CompetitorsPharming GroupNASDAQ:PHARLyell ImmunopharmaNASDAQ:LYELORIC PharmaceuticalsNASDAQ:ORICOlema PharmaceuticalsNASDAQ:OLMAGH ResearchNASDAQ:GHRSView All CompetitorsInsiders & InstitutionsMonaco Asset Management SAMSold 57,500 shares on 5/9/2024Ownership: 0.414%Picton Mahoney Asset ManagementSold 72,528 shares on 5/9/2024Ownership: 0.402%BNP PARIBAS ASSET MANAGEMENT Holding S.A.Sold 379,664,062 shares on 5/8/2024Ownership: 2.698%Russell Investments Group Ltd.Bought 41,384 shares on 5/8/2024Ownership: 0.097%ProShare Advisors LLCBought 1,499 shares on 5/8/2024Ownership: 0.021%View All Insider TransactionsView All Institutional Transactions ZYME Stock Analysis - Frequently Asked Questions Should I buy or sell Zymeworks stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Zymeworks in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ZYME shares. View ZYME analyst ratings or view top-rated stocks. What is Zymeworks' stock price target for 2024? 3 equities research analysts have issued 12 month price objectives for Zymeworks' stock. Their ZYME share price targets range from $10.00 to $16.00. On average, they expect the company's share price to reach $12.67 in the next twelve months. This suggests a possible upside of 36.8% from the stock's current price. View analysts price targets for ZYME or view top-rated stocks among Wall Street analysts. How have ZYME shares performed in 2024? Zymeworks' stock was trading at $10.39 on January 1st, 2024. Since then, ZYME stock has decreased by 10.9% and is now trading at $9.26. View the best growth stocks for 2024 here. When is Zymeworks' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our ZYME earnings forecast. How were Zymeworks' earnings last quarter? Zymeworks Inc. (NYSE:ZYME) announced its earnings results on Wednesday, March, 6th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.39) by $0.19. The firm had revenue of $16.93 million for the quarter, compared to analyst estimates of $18.32 million. Zymeworks had a negative trailing twelve-month return on equity of 28.37% and a negative net margin of 249.63%. What ETF holds Zymeworks' stock? Invesco Russell 2000 Dynamic Multifactor ETF holds 158,988 shares of ZYME stock, representing 0.37% of its portfolio. What is Ali Tehrani's approval rating as Zymeworks' CEO? 9 employees have rated Zymeworks Chief Executive Officer Ali Tehrani on Glassdoor.com. Ali Tehrani has an approval rating of 100% among the company's employees. This puts Ali Tehrani in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 86.0% of employees surveyed would recommend working at Zymeworks to a friend. What other stocks do shareholders of Zymeworks own? Based on aggregate information from My MarketBeat watchlists, some companies that other Zymeworks investors own include Advanced Micro Devices (AMD), Gilead Sciences (GILD), Just Energy Group (JE), NVIDIA (NVDA), Just Energy Group (JE), PayPal (PYPL), Alibaba Group (BABA), Cronos Group (CRON), CRISPR Therapeutics (CRSP) and Tesla (TSLA). When did Zymeworks IPO? Zymeworks (ZYME) raised $65 million in an initial public offering (IPO) on Friday, April 28th 2017. The company issued 4,500,000 shares at a price of $13.00-$16.00 per share. Citigroup, Barclays, Wells Fargo Securities and Canaccord Genuity served as the underwriters for the IPO and Cormark Securities was co-manager. Who are Zymeworks' major shareholders? Zymeworks' stock is owned by a number of institutional and retail investors. Top institutional investors include BNP PARIBAS ASSET MANAGEMENT Holding S.A. (2.70%), Empowered Funds LLC (0.42%), Monaco Asset Management SAM (0.41%), Picton Mahoney Asset Management (0.40%), Assenagon Asset Management S.A. (0.24%) and Allspring Global Investments Holdings LLC (0.20%). Insiders that own company stock include Ali Tehrani, Christopher Astle, Ecor1 Capital, Llc, Kenneth Galbraith, Neil A Klompas, Neil Josephson and Paul Andrew Moore. View institutional ownership trends. How do I buy shares of Zymeworks? Shares of ZYME stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:ZYME) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersThis 1 Biotech Stock has been shocking the marketsHuge Alerts1970’s computer coder Issues Shocking AI WarningInvestorPlaceDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDems have chosen Biden replacement?Paradigm PressThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe Crypto 9-5 Escape PlanCrypto 101 MediaThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market Insiders348 million Americans lives to END as we know it?The Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zymeworks Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
